[Possibilities of treatment reduction in Hodgkin's disease (author's transl)].
Exploratory laparotomy with splenectomy was performed before or after multiple chemotherapy in 182 patients with clinically localised Hodgkin's disease in clinical stages IB, II3A, IIB, III A and III B. There was a 50% probability of clinically not diagnosed infradiaphragmatic involvement in patients with clinically localised stage IB, II B or II3A. Restaging was necessary in 20% of patients with clinical stage III, because infradiphragmatic involvement was histologically not demonstrable. Infradiaphragmatic involvement occurred in 12% of patients who had received six chemotherapy cycles according to the MOPP scheme, before exploratory splenectomy. When chemotherapy produced complete clinical remission, only 2.7% patients had any infradiaphragmatic involvements. Exploratory laparotomy with splenectomy is not required, therefore, in such patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D008875:Middle Aged; D013156:Splenectomy
Möglichkeiten einer Therapiereduktion beim Morbus Hodgkin. II. Ermöglicht eine primäre Polychemotherapie den Verzicht auf eine explorative Splenektomie bei klinisch lokalisiertem Krankheitsbefall?